Authors

Radiation Therapy Dose for the Treatment of Patients With Lung Cancer

Walter J. Curran, Jr., MD, FACR, associate vice president of cancer, Woodruff Health Sciences Center, executive director, Winship Cancer Institute, Lawrence W. Davis Chair of Radiation Oncology, Emory University, discusses radiation therapy dose for the treatment of patients with lung cancer.

BGB-11417 +/- Zanubrutinib Demonstrates Early Efficacy Signals in CLL/SLL

Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.

PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate Cancer

With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.

FDA Issues Draft Guidance to Broaden Clinical Trial Inclusion

The FDA recently released 5 new draft guidance documents that promote broader patient eligibility for cancer clinical trials. The policies encourage inclusion of certain individuals who were previously disqualified due to medical conditions or biological factors, including brain metastases, organ dysfunction, prior or concurrent malignancies, chronic infections, and age.

Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.

Current Role of MET Inhibitors in Cancer Therapy

Emerging discoveries of MET chromosomal fusions provide additional promise as therapeutic genomic targets in MET cancer therapy and would need to be tested vigorously.

Levantinib in the Management of Differentiated Thyroid Cancer

Therapy that targets angiogenesis has been extensively investigated in differentiated thyroid cancer (DTC) and has demonstrated significant antitumor activity.

Epcoritamab/R2 Slashes Risk of FL Progression by 79%

Epcoritamab combined with rituximab and lenalidomide shows remarkable efficacy in treating relapsed follicular lymphoma, setting a new standard of care.

Nine Staff Management Essentials for Physicians

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.

Novel Delivery Systems, Unique Pairings Explored With Oncolytic Viruses

Oncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.

Pluvicto Approval Launches Theranostics in Prostate Cancer

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

Melanoma Monday: From Early Detection to Cutting-Edge Treatments

May 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.

Hillmen Analyzes Current and Upcoming Trials of BTK Inhibitors

During a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.

Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid Leukemia

Allogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.

Improved Communication Needed for Patients Living with Renal Cell Carcinoma

A lack of understanding about renal cell carcinoma (RCC), clinical trials, and the diseases psychosocial impact may exist in patients living with the illness and their families.

Tiragolumab Triplet Misses PFS in Untreated HCC

How Self-Monitoring and Data Sharing Produce Better Patient Outcomes

More than half of all patients do not remember their physicians’ recommendations and treatments unless prompted.

20 Years of Trials, Hope and Progress for Patients with Pancreatic Adenocarcinoma

In a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.

TIL Quantity Greatly Impacts Survival in Metastatic Breast Cancer

In an interview with Targeted Oncology, Daniel G. Stover, MD, highlighted the objective to enhance delivery of endocrine therapy plus CDK4/6 inhibitors to patients with hormone receptor-positive, HER2-negative breast cancer by utilizing biomarker assessments as a guide to interchange or cease treatment at the most favorable time.

World Neuroendocrine Cancer Awareness Day: Therapeutic Options for Well-differentiated NETs

Ajaz M. Khan, MD, MBA, CPE, a medical oncologist and chair of the CTCA Department of Medical Oncology, explores available treatments for patients with well-differentiated neuroendocrine tumors.

Exploring the Role of Gut Microbiome in Cancer Therapy

The normal gut microbiota metabolizes nutrients and drugs, maintains the gut mucosal barrier integrity, protects against pathogens, and trains and develops the immune system. The gut microbiome has been implicated in many human pathologies.